Atherosclerosis-related functions of C-reactive protein

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 10, Issue 4, 2010, Pages 235-240

  Agrawal, Alok ^a   Hammond Jr , David J ^a   Singh, Sanjay K ^a  

^a East Tennessee State University   (United States)

Author keywords

Atherosclerosis; C reactive protein; Enzymatically modified low density lipoprotein; Foam cells; Oxidized low density lipoprotein

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN E; C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN; MONOCLONAL ANTIBODY;

ARTICLE; ATHEROSCLEROSIS; FOAM CELL; HUMAN; MACROPHAGE; NONHUMAN; PH MEASUREMENT; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE;

EID: 79953896047     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152910793743841     Document Type: Article

References (85)

1. Agrawal, A. CRP after 2004. Mol. Immunol., 2005, 42, 927-930.
2. Singh, S.K.; Suresh, M.V.; Voleti, B.; Agrawal, A. The connection between C-reactive protein and atherosclerosis. Ann. Med., 2008, 40, 110-120.
3. Agrawal, A.; Singh, P.P.; Bottazzi, B.; Garlanda, C.; Mantovani, A. Pattern recognition by pentraxins. Adv. Exp. Med. Biol., 2009, 653, 98-116.
4. Miyazawa, K.; Inoue, K. Complement activation induced by human C-reactive protein in mildly acidic conditions. J. Immunol., 1990, 145, 650-654.
5. Singh, S.K.; Hammond Jr., D.J.; Beeler, B.W.; Agrawal, A. The binding of C-reactive protein, in the presence of phosphoethanolamine, to low-density lipoproteins is due to phosphoethanolaminegenerated acidic pH. Clin. Chim. Acta, 2009, 409, 143-144.
6. Hammond, Jr., D.J.; Singh, S.K.; Pangburn, M.K.; Potempa, L.A.; Agrawal, A. Requirement of acidic pH for the binding of Creactive protein to factor H. Mol. Immunol., 2010, 47, 2249-2249.
7. Ji, S.R.; Wu, Y.; Potempa, L.A.; Liang, Y.H.; Zhao, J. Effect of modified C-reactive protein on complement activation: a possible complement regulatory role of modified or monomeric C-reactive protein in atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol., 2006, 26, 935-941.
8. Ji, S.R.; Wu, Y.; Zhu, L.; Potempa, L.A.; Sheng, F.L.; Lu, W.; Zhao, J. Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRPm. FASEB J., 2007, 21, 284-294.
9. Eisenhardt, S.U.; Habersberger, J.; Murphy, A.; Chen, Y.-C.; Woollard, K.J.; Bassler, N.; Qian, H.; von zur Muhlen, C.; Hagemeyer, C.E.; Ahrens, I.; Chin-Dusting, J.; Bobik, A.; Peter, K. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ. Res., 2009, 105, 128-137.
10. Eisenhardt, S.U.; Thiele, J.R.; Bannasch, H.; Stark, G.B.; Peter, K. C-reactive protein: how conformational changes influence inflammatory properties. Cell Cycle, 2009, 8, 3885-3892.
11. Wang, H.W.; Sui, S.F. Dissociation and subunit rearrangement of membrane-bound human C-reactive proteins. Biochem. Biophys. Res. Comm., 2001, 288, 75-79.
12. Wang, H.W.; Wu, Y.; Chen, Y.; Sui, S.F. Polymorphism of structural forms of C-reactive protein. Int. J. Mol. Med., 2002, 9, 665-671.
13. Blizniukov, O.P.; Kozmin, L.D.; Falikova, V.V.; Martynov, A.I.; Tischenko, V.M. Effect of Ca2+ ions on hydrodynamic properties of pentamer and decamer of C-reactive protein in solution. Mol. Biol., 2003, 37, 1071-1079.
14. Kushner, I.; Elyan, M. Why does C-reactive protein predict coronary events? Am. J. Med., 2008, 121, e11-e11.
15. Casas, J.P.; Shah, T.; Hingorani, A.D.; Danesh, J.; Pepys, M.B. Creactive protein and coronary heart disease: a critical review. J. Intern. Med., 2008, 264, 295-314.
16. Schunkert, H.; Samani, N.J. Elevated C-reactive protein in atherosclerosis-chicken or egg? N. Engl. J. Med., 2008, 359, 1953-1955.
17. Galkina, E.; Ley, K. Immune and inflammatory mechanisms of atherosclerosis. Annu. Rev. Immunol., 2009, 27, 165-197.
18. Leake, D.S. Does an acidic pH explain why low density lipoprotein is oxidised in atherosclerotic lesions? Atherosclerosis, 1997, 129, 149-157.
19. Björnheden, T.; Levin, M.; Evaldsson, M.; Wiklund, O. Evidence of hypoxic areas within the arterial wall in vivo. Arterioscler. Thromb. Vasc. Biol., 1999, 19, 870-876.
20. Naghavi, M.; John, R.; Naguib, S.; Siadaty, M.S.; Grasu, R.; Kurian, K.C.; Van Winkle, W.B.; Soller, B.; Litovsky, S.; Madjid, M.; Willerson, J.T.; Cascells, W. pH heterogeneity of human and rabbit atherosclerotic plaques: a new insight into detection of vulnerable plaque. Atherosclerosis, 2002, 164, 27-35.
21. Sneck, M.; Kovanen, P.T.; Öörni, K. Decrease in pH strongly enhances binding of native, proteolyzed, lipolyzed, and oxidized low density lipoprotein particles to human aortic proteoglycans. J. Biol. Chem., 2005, 280, 37449-37454.
22. Haka, A.S.; Grosheva, I.; Chiang, E.; Buxbaum, A.R.; Baird, B.A.; Pierini, L.M.; Maxfield, F.R. Macrophages create an acidic extracellular hydrolytic compartment to digest aggregated lipoproteins. Mol. Biol. Cell., 2009, 20, 4932-4940.
23. Pepys, M.B.; Hirschfield, G.M. C-reactive protein: a critical update. J. Clin. Invest., 2003, 111, 1805-1812.
24. Reynolds, G.D.; Vance, R.P. C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. Arch. Pathol. Lab. Med., 1987, 111, 265-269.
25. Hatanaka, K.; Li, X.-A.; Masuda, K.; Yutani, C.; Yamamoto, A. Immunohistochemical localization of C-reactive protein-binding sites in human atherosclerotic aortic lesions by a modified streptavidin-biotin-staining method. Pathol. Int., 1995, 45, 635-641.
26. Bhakdi, S.; Torzewski, M.; Klouche, M.; Hemmes, M. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler. Thromb. Vasc. Biol., 1999, 19, 2348-2354.
27. Zhang, Y.X.; Cliff, W.J.; Schoefl, G.I.; Higgins, G. Coronary Creactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis, 1999, 145, 375-379.
28. Torzewski, M.; Rist, C.; Mortensen, R.F.; Zwaka, T.P.; Bienek, M.; Waltenberger, J.; Koenig, W.; Schmitz, G.; Hombach, V.; Torzewski, J. C-reactive protein in the arterial intima: role of Creactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 2094-2099.
29. Sun, H.; Koike, T.; Ichikawa, T.; Hatakeyama, K.; Shiomi, M.; Zhang, B.; Kitajima, S.; Morimoto, M.; Watanabe, T.; Asada, Y.; Chen, Y.E.; Fan, J. C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am. J. Pathol., 2005, 167, 1139-1148.
30. Norja, S.; Nuutila, L.; Karhunen, P.J.; Goebeler, S. C-reactive protein in vulnerable coronary plaques. J. Clin. Pathol., 2007, 60, 545-548.
31. Turk, J.R.; Carroll, J.A.; Laughlin, M.H.; Thomas, T.R.; Casati, J.; Bowles, D.K.; Sturek, M. C-reactive protein correlates with macrophage accumulation in coronary arteries of hypercholesterolemic pigs. J. Appl. Physiol., 2003, 95, 1301-1304.
32. Paul, A.; Ko, K.W.; Li, L.; Yechoor, V.; McCrory, M.A.; Szalai, A.J.; Chan, L. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation, 2004, 109, 647-655.
33. Fukuchi, Y.; Miura, Y.; Nabeno, Y.; Kato, Y.; Osawa, T.; Naito, M. Immunohistochemical detection of oxidative stress biomarkers, dityrosine, and n-(hexanoyl)lysine, and C-reactive protein in rabbit atherosclerotic lesions. J. Atheroscler. Thromb., 2008, 15, 185-192.
34. Koike, T.; Kitajima, S.; Yu, Y.; Nishijima, K.; Zhang, J.; Ozaki, Y.; Morimoto, M.; Watanabe, T.; Bhakdi, S.; Asada, Y.; Chen, Y.E.; Fan, J. Human C-reactive protein does not promote atherosclerosis in transgenic rabbits. Circulation, 2009, 120, 2088-2094.
35. Krijnen, P.A.J.; Ciurana, C.; Cramer, T.; Hazes, T.; Meijer, C.J.L.M.; Visser, C.A.; Niessen, H.W.M.; Hack, C.E. IgM colocalizes with complement and C-reactive protein in infracted human myocardium. J. Clin. Pathol., 2005, 58, 382-388.
36. Meuwissen, M.; van der Wal, A.C.; Niessen, H.W.M.; Koch, K.T.; de Winter, R.J.; van der Loos, C.M.; Rittersma, S.Z.H.; Chamuleau, S.A.J.; Tijssen, J.G.P.; Becker, A.E.; Piek, J.J. Colocalization of intraplaque C reactive protein, complement, oxidised low density lipoprotein, and macrophages in stable and unstable angina and acute myocardial infarction. J. Clin. Pathol., 2006, 59, 196-201.
37. Zimmermann, O.; Bienek-Ziolkowski, M.; Wolf, B.; Vetter, M.; Baur, R.; Mailänder, V.; Hombach, V.; Torzewski, J. Myocardial inflammation and non-ischaemic heart failure: is there a role for Creactive protein? Basic Res. Cardiol., 2009, 104, 591-599.
38. Diehl, E.E.; Haines 3rd, G.K.; Radosevich, J.A.; Potempa, L.A. Immunohistochemical localization of modified C-reactive protein antigen in normal vascular tissue. Am. J. Med. Sci., 2000, 319, 79-83.
39. Volanakis, J.E.; Kaplan, M.H. Specificity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide. Proc. Soc. Exp. Biol. Med., 1971, 136, 612-614.
40. Chang, M.K.; Binder, C.J.; Torzewski, M.; Witztum, J.L. Creactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc. Natl. Acad. Sci. USA, 2002, 99, 13043-13048.
41. Taskinen, S.; Kovanen, P.T.; Jarva, H.; Meri, S.; Pentikäinen, M.O. Binding of C-reactive protein to modified low-density-lipoprotein particles: identification of cholesterol as a novel ligand for Creactive protein. Biochem. J., 2002, 367, 403-412.
42. Biró, A.; Thielens, N.M.; Cervenák, L.; Prohászka, Z.; Füst, G.; Arlaud, G.J. Modified low density lipoproteins differentially bind and activate the C1 complex of complement. Mol. Immunol., 2007, 44, 1169-1177.
43. Singh, S.K.; Suresh, M.V.; Prayther, D.C.; Moorman, J.P.; Rusinol, A.E.; Agrawal, A. C-reactive protein-bound enzymatically modified low-density lipoprotein does not transform macrophages into foam cells. J. Immunol., 2008, 180, 4316-4322.
44. Taskinen, S.; Hyvönen, M.; Kovanen, P.T.; Meri, S.; Pentikäinen, M.O. C-reactive protein binds to the 3-OH group of cholesterol in LDL particles. Biochem. Biophys. Res. Comm., 2005, 329, 1208-1216.
45. Van Tits, L.; de Graaf, J.; Toenhake, H.; van Heerde, W.; Stalenhoef, A. C-reactive protein and annexin A5 bind to distinct sites of negatively charged phospholipids present in oxidized lowdensity lipoprotein. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 717-722.
46. Rufail, M.L.; Ramage, S.C.; van Antwerpen, R. C-reactive protein inhibits in vitro oxidation of low-density lipoprotein. FEBS Lett., 2006, 580, 5155-5160.
47. Tabuchi, M.; Inoue, K.; Usui-Kataoka, H.; Kobayashi, K.; Teramoto, M.; Takasugi, K.; Shikata, K.; Yamamura, M.; Ando, K.; Nishida, K.; Kasahara, J.; Kume, N.; Lopez, L.R.; Mitsudo, K.; Nobuyoshi, M.; Yasuda, T.; Kita, T.; Makino, H.; Matsuura, E. The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis. J. Lipid Res., 2007, 48, 768-781.
48. Singh, U.; Dasu, M.R.; Yancey, P.G.; Afify, A.; Devaraj, S.; Jialal, I. Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats. J. Lipid Res., 2008, 49, 1015-1023.
49. Ji, S.R.; Wu, Y.; Potempa, L.A.; Qiu, Q.; Zhao, J. Interactions of C-reactive protein with low-density lipoproteins: implications for an active role of modified C-reactive protein in atherosclerosis. Int. J. Biochem. Cell Biol., 2005, 38, 648-661.
50. Agrawal, A.; Singh, S.K.; Thompson, J.A.; Hammond, D.J.; Rusinol, A.E. Requirements for the binding of C-reactive protein to oxidized low-density lipoprotein. FASEB J., 2009, 23, 1006.2.
51. Singh, S.K.; Suresh, M.V.; Prayther, D.C.; Moorman, J.P.; Rusinol, A.E.; Agrawal, A. Phosphoethanolamine-complexed C-reactive protein: a pharmacological-like macromolecule that binds to native low-density lipoprotein in human serum. Clin. Chim. Acta, 2008, 394, 94-98.
52. De Beer, F.C.; Soutar, A.K.; Baltz, M.L.; Trayner, I.M.; Feinstein, A.; Pepys, M.B. Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J. Exp. Med., 1982, 156, 230-242.
53. Nunomura, W.; Hatakeyama, M. Binding of low density lipoprotein (LDL) to C-reactive protein (CRP): a possible binding through apolipoprotein B in LDL at phosphorylcholine-binding site of CRP. Hokkaido J. Med. Sci., 1990, 65, 474-480.
54. Fu, T.; Borensztajn, J. Macrophage uptake of low-density lipoprotein bound to aggregated C-reactive protein: possible mechanism of foam-cell formation in atherosclerotic lesions. Biochem. J., 2002, 366, 195-201.
55. Cabana, V.G.; Gewurz, H.; Siegel, J.N. Interaction of very low density lipoproteins (VLDL) with rabbit C-reactive protein. J. Immunol., 1982, 128, 2342-2348.
56. Toh, C.H.; Samis, J.; Downey, C.; Walker, J.; Becker, L.; Brufatto, N.; Tejidor, L.; Jones, G.; Houdijk, W.; Giles, A.; Koschinsky, M.; Ticknor, L.O.; Paton, R.; Wenstone, R.; Nesheim, M. Biphasic transmittance waveform in the APTT coagulation assay is due to the formation of a Ca++-dependent complex of C-reactive protein with very-low-density lipoprotein and is a novel marker of impending disseminated intravascular coagulation. Blood, 2002, 100, 2522-2529.
57. Fujita, Y.; Kakino, A.; Nishimichi, N.; Yamaguchi, S.; Sato, Y.; Machida, S.; Cominachini, L.; Delneste, Y.; Matsuda, H.; Sawamura, T. Oxidized LDL receptor LOX-1 binds to C-reactive protein and mediates its vascular effects. Clin. Chem., 2009, 55, 285-294.
58. Shih, H.H.; Zhang, S.; Cao, W.; Hahn, A.; Wang, J.; Paulsen, J.E.; Harnish, D.C. CRP is a novel ligand for the oxidized LDL receptor LOX-1. Am. J. Physiol. Heart Circ. Physiol., 2009, 296, H1643-1650.
59. Udvarnoki, K.; Cervenak, L.; Uray, K.; Hudecz, F.; Kacskovics, I.; Spallek, R.; Singh, M.; Füst, G.; Prohászka, Z. Antibodies against C-reactive protein cross-react with 60-kilodalton heat shock proteins. Clin. Vaccine Immunol., 2007, 14, 335-341.
60. Brown, M.S.; Goldstein, J.L. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu. Rev. Biochem., 1983, 52, 223-261.
61. Zwaka, T.P.; Hombach, V.; Torzewski, J. C-reactive proteinmediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation, 2001, 103, 1194-1197.
62. Verma, S.; Li, S.H.; Badiwala, M.V.; Weisel, R.D.; Fedak, P.W.M.; Li, R.K.; Dhillon, B.; Mickle, D.A. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of Creactive protein. Circulation, 2002, 105, 1890-1896.
63. Schwedler, S.B.; Hansen-Hagge, T.; Reichert, M.; Schmiedeke, D.; Schneider, R.; Galle, J.; Potempa, L.A.; Wanner, C.; Filep, J.G. Monomeric C-reactive protein decreases acetylated LDL uptake in human endothelial cells. Clin. Chem., 2009, 55, 1728-1731.
64. Mookerjea, S.; Francis, J.; Hunt, D.; Yang, C.Y.; Nagpurkar, A. Rat C-reactive protein causes a charge modification of LDL and stimulates its degradation by macrophages. Arterioscler. Thromb., 1994, 14, 282-287.
65. Hirschfield, G.M.; Gallimore, J.R.; Kahan, M.C.; Hutchinson, W.L.; Sabin, C.A.; Benson, G.M.; Dhillon, A.P.; Tennent, G.A.; Pepys, M.B. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc. Natl. Acad. Sci. USA, 2005, 102, 8309-8314.
66. Reifenberg, K.; Lehr, H.A.; Baskal, D.; Wiese, E.; Schaefer, S.C.; Black, S.; Samols, D.; Torzewski, M.; Lackner, K.J.; Husmann, M.; Blettner, M.; Bhakdi, S. Role of C-reactive protein in atherogenesis: can the apolipoprotein E knockout mouse provide the answer? Arterioscler. Thromb. Vasc. Biol., 2005, 25, 1641-1646.
67. Trion, A.; de Matt, M.P.M.; Jukema, J.W.; van der Laarse, A.; Mass, M.C.; Offerman, E.H.; Havekes, L.M.; Szalai, A.J.; Princen, H.M.G.; Emeis, J.J. No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E* 3-leiden /human C-reactive protein transgenic mice. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 1635-1640.
68. Schwedler, S.B.; Amann, K.; Wernicke, K.; Krebs, A.; Nauck, M.; Wanner, C.; Potempa, L.A.; Galle, J. Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout mice. Circulation, 2005, 112, 1016-1023.
69. Tennent, G.A.; Hutchinson, W.L.; Kahan, M.C.; Hirschfield, G.M.; Gallimore, J.R.; Lewin, J.; Sabin, C.A.; Dhillon, A.P.; Pepys, M.B. Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/-mice. Atherosclerosis, 2008, 196, 248-255.
70. Ortiz, M.A.; Campana, G.L.; Woods, J.R.; Boguslawski, G.; Sosa, M.J.; Walker, C.L.; Labarrere, C.A. Continuously-infused human C-reactive protein is neither proatherosclerotic nor proinflammatory in apolipoprotein E-deficient mice. Exp. Biol. Med., 2009, 234, 624-631.
71. Kovacs, A.; Tornvall, P.; Nilsson, R.; Tegnér, J.; Hamsten, A.; Björkegren, J. Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia. Proc. Natl. Acad. Sci. USA, 2007, 104, 13768-13773.
72. Torzewski, M.; Reifenberg, K.; Cheng, F.; Wiese, E.; Küpper, I.; Crain, J.; Lackner, K.J.; Bhakdi, S. No effect of C-reactive protein on early atherosclerosis in LDLR-/-/human C-reactive protein transgenic mice. Thromb. Haemost., 2008, 99, 196-201.
73. Singh, V.; Tiwari, R.L.; Dikshit, M.; Barthwal, M.K. Models to study atherosclerosis: a mechanistic insight. Curr. Vasc. Pharmacol., 2009, 7, 75-109.
74. Pasceri, V.; Willerson, J.T.; Yeh, E.T.H. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation, 2000, 102, 2165-2168.
75. Sternik, L.; Samee, S.; Schaff, H.V.; Zehr, K.J.; Lerman, L.O.; Holmes, D.R.; Herrmann, J.; Lerman, A. C-reactive protein relaxes human vessels in vitro. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 1865-1868.
76. Verma, S.; Devaraj, S.; Jialal, I. C-reactive protein promotes atherothrombosis. Circulation, 2006, 113, 2135-2150.
77. Bisoendial, R.J.; Kastelein, J.J.P.; Peters, S.L.M.; Levels, J.H.M.; Birjmohun, R.; Rotmans, J.I.; Hartman, D.; Meijers, J.C.M.; Levi, M.; Stroes, E.S.G. Effects of CRP infusion on endothelial function and coagulation in normocholesterolemic and hypercholesterolemic subjects. J. Lipid Res., 2007, 48, 952-960.
78. Doronzo, G.; Russo, I.; Trovati, M.; Anfossi, G. Sodium azide in commercially available C-reactive protein preparations does not influence matrix metalloproteinase-2 synthesis and release in cultured human aortic smooth muscle cells. Clin. Chem., 2006, 52, 1200-1201.
79. Dasu, M.R.; Devaraj, S.; Du Clos, T.W.; Jialal, I. Biological effects of C-reactive protein are not due to endotoxin contamination: evidence from Toll-like receptor 4 knock-down human aortic endothelial cells. J. Lipid Res., 2007, 48, 509-512.
80. Paffen, E.; Vos, H.L.; Bertina, R.M. C-reactive protein does not directly induce tissue factor in human monocytes. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 975-981.
81. Taylor, K.E.; Giddings, J.C.; van den Berg, C.W. C-reactive protein-induced in vitro endothelial cell activation is an artifact caused by azide and lipolysaccharide. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 1225-1230.
82. Swafford Jr., A.N.; Bratz, I.N.; Knudson, J.D.; Rogers, P.A.; Timmerman, J.M.; Tune, J.D.; Dick, G.M. C-reactive protein does not relax vascular smooth muscle cell: effects mediated by sodium azide in commercially available preparations. Am. J. Physiol. Heart Circ. Physiol., 2005, 288, H1786-H1795.
83. Pepys, M.B.; Hawkins, P.N.; Kahan, M.C.; Tennent, G.A.; Gallimore, J.R.; Graham, D.; Sabin, C.A.; Zychlinsky, A.; de Diego, J. Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ. Res., 2005, 97, e97-e103.
84. Khreiss, T.; Jozsef, L.; Potempa, L.A.; Filep, J.G. Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation, 2004, 109, 2016-2022.
85. Scirica, B.M.; Morrow, D.A. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation, 2006, 113, 2128-2134.